VIR - Earnings call 3 2023 | Vir Biotechnology, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer.

You may begin, Ms. Damouni Ellis.

Sasha Damouni Ellis

Thank you, and good afternoon. Dr. are today me With Marianne De Officer; Chief Executive Dr. Backer, are and Chief like under Financial Pang, statements remind Chief we the Lee, Officer; Medical we the of would Phil securities Officer.Before laws. forward-looking Sung begin, that some today making are everyone statements to I These involve implied significantly differ from and expressed or substantial uncertainties our statements. could cause to forward-looking development or programs, achievements such statements by forward-looking clinical future risks that results, performance those business XX-K, uncertainties are filed turn and risks X-K.I our and to company's and with our CEO, will over in risks reports described These with Exchange associated the Commission, XX-Q now Securities the call Dr. including the Forms and Backer. De Marianne

Marianne De Backer

pleased is last The those with welcome. progress Boston today. Good to this encouraging you, and updates most to our especially positive disease needs momentum to to Marianne time afternoon trials you I'm Thank our I'm Since our All Vir driving all pipeline impressive we multiple here in first some Backer, and your has are made clinical medical CEO this areas AASLD in spoke, attention looking serve patients infectious who are the call as at the De all beyond.Let platforms, unmet Liver Sasha. waiting, me scientific the welcome on of and Vir, Meeting we we and later forward seek month. forward.

most hepatitis data advanced Our and chronic X hepatitis our programs, Phase X delta. readouts of from chronic B

and VIR-XXXX, XX trial, with data Part As peginterferon looking where weeks antibody, our a B and of MARCH our for alpha. we combinations of reminder, are siRNA, this XX without the VIR-XXXX, at and from includes initial monoclonal

combination combination breadth who have funding, This investigational approximately trial, includes evaluating delta we development these patients viral antibody forward potency, of the virus.Thanks of the can our through of a which I. the had $XX positive ongoing look to chronic our momentum distinct non-dilutive VIR-XXXX siRNA viable funding, are development $XX be or VIR-XXXX, VIR-XXXX Project support which data hepatitis co-infected from new the antibody also Phase for will our to initial million inescapability. our monoclonal alone, therapy We of is alone, and NextGen whether sharing SOLSTICE COVID-XX a next-generation in BARDA VIR-XXXX in on million funding with with

pursuit Gates because Network, Trials which HIV and step Institute the Foundation, and us in & one Allergy which it closer field Bill enabling National is will Phase highly the new the the cell broad, ability platform one prevention investigational the to Phase a as antibody the to antibody powerful in and trial expect testament benefit potent with to another partnership to antibody newest gears such especially We was world-class hope trial this trial antibodies the an of our generating also vaccine monoclonal medicines.Switching of and novel alternative monoclonal a Vaccine with revolutionize therapeutics Diseases HIV antibodies, brings Melinda our of technologies ultimate access Vir's in meaningful the post in and of of be funding include developing Infectious HIV. our to first development discover for we programs, ease. our the initiate participant supporters, Phase I of I.The and VIR-XXXX, T delivery the funding XXXX, dosed potential have I antibody BARDA of for supports shared monoclonal RNA-delivered This exploring greater This evaluating an clinical patient vaccine. is rare, September, the of

of sharing you will HIV strategic initial the of and want the I made forward We give are impact. into trial decisions second to our approach prevention, this public look hopeful from health growth half and future close some in that increase to patient Vir to we data help in XXXX.Finally, longstanding transformative drive unique the will has a gap glimpse

mission world our disease, to you powering was we transform and a vision, founding immune without lives. know, on are infectious the system As a now broader embarking

Vice We to expand ready our that by is immunology monoclonal and of the antibodies possible have immunology selectivity created and ourselves we for Targeting joining as already This Senior existing Dr. autoimmune already of growth X with oncology. of in-house company enhanced Korman, immunotherapy in Vir. drugs an are beyond enhanced led have Alan platform advancing our seen of approved Alan infectious potency, Vir, first for and with selectivity always the expertise using AI-based immune-oncology at areas augmented and has applications Immune and into here first now tumor leadership antibodies disease immuno-oncology. new are made protein with applying the deep to by diseases President under engineering.We experience, potency Prior discovery

disease.I is Academy will to as to us be early thank be Meanwhile, in investments opportunities. programs as spend in updated complementary development bring proven leadership of on also to judicious keeping want from be to track Pang critical preclinical evaluate will Research. Officer the record highlight Chief bringing to well infectious clinical way reach, her his at priority platform and late-stage Medical T bringing research hepatitis scientific of sheet, will drug tumor fruition, you expertise, an affairs core Phil XX our by points, external chronic continue and delta and forward. with billion deployment National to new now Phil Chief delivering to through XXXX.We Dr. forward antibody strong to innovation lead and on maximize thanks drug and Officer, next Town. development. progress agnostic in Head are programs. to therapeutics Jennifer that this We our top brings on of development novel the to will immunology which invest This Jennifer we than ensure $X.X embarking Scientific clinical expanding Vir.With a clinical in our to that inflection we over medical investigational research, look IND strategy cash of X antigens, we investments.Finally, combined as innovative We Phil candidates all R&D and of external our Lanzavecchia. of Dr. developing medicines welcoming provide for our our decades immunologist, take to continue Her want to in applications our B more I'll as week, specific and led successfully the I Sciences balance identify a for is hepatitis we this Antonio our that, cell responsibilities update breakthrough to allows and to an experience preclinical new and effort portfolio our the turn believe receptors multiple to chronic call which making beyond within includes our on for go experience, Interim are deep and

Phil Pang

Marianne. you, Thank

are looking to II As trial. AASLD data we B from MARCH mentioned, and II hepatitis Marianne our forward SOLSTICE at delta Phase our Phase hepatitis chronic sharing trial chronic

functional hepatitis B. welcomed XXX results a and living with finite time. the cure I treatment, would to the a in to achieve chronic a B cure only X% and goal, of X% of of only The is goal to the about achieve as First, after by virus cure, talk hepatitis that a defined functional be our people want control arduous functional duration lifelong chronic a which to available treatment is million

to the bar achieving functional aiming rate. or are of goal much a We the better set higher cure XX% with

in really has antivirals. both hypothesis VIR-XXXX with Our cure action. our multiple trials.Our mechanisms our a and X need an with but VIR-XXXX what immunomodulator, cannot evaluating achieve and antibody antiviral mechanism both or can is you potentially which as that exactly action, only siRNA you functional VIR-XXXX is clinical only act vaccinal are ongoing an immunomodulators we of

First, viral entry variants. it HBV preventing is a and neutralizing of HDV antibody,

from it particles via Second, subviral bloodstream. particles and enhanced optimization, viral the removes

an potential which VIR-XXXX act tolerogen, domain, down, can capable can immune create a by vaccinal also down HDV. a on allows as to an immune activator, the has potential it as by is unleash stimulating known immunomodulator RNA of knocking direct HBV a hepatitis it dendritic the HBV Third, is otherwise antiviral act against modified as cells act mature can This or we cells because as to effect.VIR-XXXX we vitro and antigen system. in immune it knocking T brake HBV the believe of surface protein B and transcripts. Fc

act, to designed is checkpoint inhibitor. analogy, VIR-XXXX like by So, a

treatment We and sustained surface the have about about loss hepatitis VIR-XXXX of that had weeks, for at XX plus when demonstrated peginterferon is after XX alpha XX% achieved XX% surface participants of end weeks end the treatment. loss antigen B hepatitis antigen given of B

end In in declines based of study, the a study, just first XX largest VIR-XXXX, without functional you, hepatitis combination response their of on a Vir also off-treatment peginterferon B levels alpha antigen with at the to additive that we fundamental VIR-XXXX date weeks combining able X% after VIR-XXXX the this To endogenous at without the antibody our resulted the potential small, Part siRNAs after remind to we evaluating cure VIR-XXXX. for for observed impact on of In are with antibody specifically MARCH and B XX of hepatitis that that surface rates. achieved who was of of XX monoclonal demonstrate treatment. the the VIR-XXXX. same weeks. are is an and vaccinal XX and B role an have of Thus, plus of alpha surface siRNA around will antibody, weeks loss combination impact may VIR-XXXX peginterferon VIR-XXX of antigen the AASLD, to participants relatively we This in anti-HBs Although the treatment.Vir predict treated questions have end plus saw patients is the be therapy. demonstration identified first ever that number can

see will patients inhibit our be siRNA for liver of currently achieve XX therapy believe XXX,XXX virus a of strongly hepatitis to XXX,XXX potentially suppressive XX% role of or cancer VIR-XXXX Xx in First, let's Third, than of This delta. we B. patients Notably, potentially risk hepatitis the also About chronic this better be to than the treatment full and HBV-HDV available will hepatitis people of VIR-XXXX more, over curative forms greater if alpha, of shift with RNA life for estimated have viral of immunomodulatory likely is In are greater the We functional we're hepatitis give XX% need, add greater hepatitis after the delta. see requires This VIR-XXXX Delta Second, we daily regimen.Now, so, yet therapy peginterferon have will to regimen having hepatitis weeks chronic with of effect? the the potent also of If viral in for some co-infection. weeks with see VIR-XXXX response will drive severe we diagnosed. treatment approval.Our would given and desire replace the there rates that cycle to treatment benefit. Xx hepatitis compared don't B vaccinal a of undetectable signs can under-diagnosis objections. accelerated medical we X%? requires one death of VIR-XXXX, VIR-XXXX support delta States infectious. lifelong HDV end an United efficacious, suggestive underestimate, are gears if receiving the VIR-XXXX most of treatment. and unmet recognition in to potential chronic delta. any for peginterferon highly we we be to XX only easy-to-use delta delta risk a is an Notably, surface paths chronic antigen of subcutaneous activity an chronic urgent we plus X%? a to hepatitis EUX the end response antibody if currently to because alpha

to we challenged efficacy, safety have to from suppressive that I'm oral is terms can trial there. excited not tolerability. but presentation ourselves better, also if terms shared a in of and Data get as a We of the develop SOLSTICE in therapy AASLD. chronic late-breaker just convenience, be will see at

the technology. clinic monoclonal next-generation encode about body protein next-generation ahead participants.Looking and in against, Instead and must COVID-XX of an of a enter will in response antibody, immune is Specifically, a BARDA. to you.Finally, a the quick then by and what that of which cells or X VIR-XXXX, cohort funding alone, VIR-XXXX combination VIR-XXXX. antiviral includes funded RNAs next antibody efficacy own VIR-XXXX alone, your combination the of actually the be the part research using we safety develop evaluating RNA-encoding encode such that investigational to small RNA antibody, This as this RNA RNA back. parallel will believe RNA we and the potentially directly your is antibody This our self-amplifying being defends development of is circular be allowing to would together ultimate make this look of would that

know prophylactic As remain there questions A VIR-XXXX, investigational our I influenza antibody. about

have important analyses X the following Our ongoing post-hoc yielded insights.

cases illness is First, for case includes VIR-XXXX's flu ability how symptomatic the to X,XXX-milligram dose improved of when definition XX% is reduce to fever, defined. the symptomatic that

for Second, XX% dosing.Notably, cases all more to this antivirals, of its our a it not neuraminidase candidates is XX XXXX.In covers the filing next-generation that A we monoclonal occur the virus flu VIR-XXXX but to in to when IND is further antibody VIR-XXXX vivo VIR-XXXX, and respiratory relative metapneumovirus. VIR-XXXX The risk excluding has been an in addition have reduction second that of only other increases current we preclinical is potent the against flu few and submission is like Furthermore, clinically action for enzyme human months. days and flu VIR-XXXX, an XX validated B. of because expect half derisked. within and both flu syncytial IND in antibody, mechanism anticipated of next the X inhibits investigational

have in have mAb causes available antibody single you also RSV, infants. a RSV. currently that for significant may mortality if metapneumovirus, only demand human that a also and could heard covers surrounding monoclonal morbidity not the of but You virus, the second the news incredible Imagine

have We have squamous at very called an vaccine novel candidate epithelial that intelligent HPV VIR-XXXX.Our lesions executing, pre-cancer and busy therapeutic cancers control of and also high-grade researchers Vir is the here Town as investigational doubt will mindset.I Jennifer innovation will for reins bolster no now Scientific over over Officer, to call Sung Lee. turn Chief excited our hand the She Financial to Officer. I'm Chief further been to

Sung Lee

reason the share $X.X Bill. financial compared ago. revenues of decline for our for compared We're year a quarter collaboration The same $XXX.X is ago. year were to to million to million the period Thank revenues a for the primary XXXX. you, results pleased sotrovimab lower third from Total

of of third to reported same in million ended quarter to were investments the compensation.For to R&D hepatitis $XX.X we With III manufacturing to in driven We SG&A and VIR-XXXX, the quarter were to XXXX, compared expenses make continue The our to $XXX.X consulting delta. efforts to this costs compared million expenses our net primarily and studies for which us. we of decline period the revenues end due XXXX In contribution ongoing collaboration the the period billion negative stock-based ongoing a our in.Turning Other an flu GSK, investments levels in in expenses of required million the operating the expense million authorization $XX.X million second to sotrovimab, of quarter $XXX.X billion $XXX.X in II to compared third cash growth the for for in the potentially was investigational quarter at million VIR-XXXX by in hepatitis of in third minimal quarter the a period recorded be same expense year-over-year of balance XXXX expect cancellation and $X.X for Phase expenses, partner, same of with of XXXX, were XXXX our and investments XXXX. support marketing the line $XXX.X XXXX. we compared a third sheet, of lower $XX.X to the antibody. related the to million of recorded, leads top Phase are B the consolidated XXXX. of quarter third income behind net at of monoclonal $X.XX of activities to now XXXX.Turning the largely loss the drivers

GSK, liability this made were as During quarter, payment, sotrovimab effectively for the GSK we is which to manufacturing liability and recorded With supply to originally capacity, XXXX. off. our excess a collaborator, $XX in of million payment a third the paid recent

our measures to payment the during capital would closing, the are to was $XX and we structure add cash to Excluding utilization million.In taking approximately third optimize that our I GSK, allocation. like quarter cost

can Sasha. allocation to will back be disciplined You management.I turn strong and approach to now have call and capital capital stewards us a continue to expense the of to expect

Sasha Damouni Ellis

Thank Sung. you,

the please are all so now Q&A get will Please per to of able covering We start analysts. open the up to limit to person we Operator, lines. that questions X our section.

Operator

from Wang of line Our come will Barclays. first Gena question the with

Huidong Wang

questions. question a I Marianne. One have X is for picture big

regarding you for general, you're expand second that looking Phil and more for XX% mentioned to over mentioned correctly, question indications?And wanted you selecting with key for update. that functional the you So, hear say, rationale autoimmune AASLD focus you cure. strategic lead share diseases on Could -- my And you is HBV, in if I us immuno-oncology. your for the,

MARCH particular we above this on months that be be know is treatment, treatment, completed that a this after for for be XX%? bar data, initial say, looking the you so So, X will we that maintain, given treatment, can what B will Part still so of could

Marianne De Backer

Thank you Maybe Appreciate very that questions. first Gena. on the big one mentioned. you much, picture those

our an products Vir ever unmet you company, first company. Vir become And integrated with immunology founded, know, address as have to ambition of at commercial was here course, we since is seen significant an as ourselves patient need. So, and that

need aiming system's at focused we is what entirely bolster years, first the in was doing on X immune ability only So, disease. to And clearly, been that always have the in Vir fight infectious addressing to disease. unmet

focused and are where fight exactly very to in cancer we broader same such of and build starting [ really awry make T as However, has or in to immune want well a as to not at prepared a way ] scratch. those of was know, here have who to outfit immuno-oncology, cell have under mentioned working, being who antibody targeting really in for in immunologist, receptors world technologies blockbusters cell T X the very cell YERVOY tools my system agnostic here he really already my Alan leadership powerful renowned immune We platforms platform, identify have can example, antigen. you discovered BMS. use on also tumor a really platform, oncology again, Antonio also on to also, B much those type disease. Korman, to team and we area. small as introductory from We impact OPDIVO, diseases Lanzavecchia, the novel of comments, had specific autoimmune we address we is in immune as comments, an system is the mentioned bought some we person the to a gone a the of specific balance and on And And while the a who, and

immune other turning everyone AASLD. where I as we lot start technology AASLD to want And have, we infectious with reading to to that ourselves will your little example, platform using is a we interaction machine build system where to that with to also learning, and disease, color all patient to for updates, sure come here knowledge we but also question of great maybe exploring and more that a in provide AI to we So, the just second and limit reminding need.Now, Phil just not significant what exploring on will have areas bit mostly, of then enhance that on. that at I do there make cells antibodies the out be we unmet would invite the from,

add combining and an hepatitis to a replace in remind that's a regimen an with on have immunomodulator effect be in that And B so as our would the you after functional cure the if We would -- we a has able we we where weeks combination. XX% then hypothesis for were you highest initially loss replace actually antiviral interferon it in comments, we could would to it our thus interferon answer wanted look that functional by alpha everyone sustained potentially with for antigen if to would XXXX, S-antigen to just hepatitis mentioned off we patients. So, to X% look of regimen. cure or shown would what only the could at been really And testing if to started X%, exert siRNA, that question, rate? antibody, we like alpha, we antibody whether B, field. significant Phil alpha started add chronic And his prepared increase interferon treatment looking ourselves, would to rates by far go if our in what or that thus reported far and this loss like XXXX, added XX

we we delivering only A, an trial, could And question. and So that antibody the see regimens, X siRNA additive A XX short in in combining with Part treatments, weeks of that started short Part really MARCH effects. initial MARCH answering and our is again,

log X.X and signals were decline date. achieved safety in there no You to S-antigen, seen

to there durations, same and of now results our So, that lot that AASLD. peginterferon, look ask Phil with without is XX for the intro, want B Part expect exploring actually to gave color us XX a and longer to confidence to where combination more are forward bit what at treatment but with to I provide we a little perhaps weeks.And

Phil Pang

and you, for you, Marianne, the thank question. Thank Gena,

put So, statements varying context much rates which off-treatment couple is that its maybe a I'll from on-treatment predicting in in infancy. still rates is first, response of

had more the from of presentation was to off-treatment on-treatment an first As hint endogenous you the were you was from predictor And response. a times response of any anti-HBS you our of were response. demonstrate that we likely if EASL, there previous one have first an response, know, off-treatment at that to

that functional XXXX regimens be statement, at all have AASLD, a XXXX a to think really forward, of off-treatment say important a and looking to what's for in that, there can if at.But greater generally proven response or response, be that looking higher, that in just I on-treatment for course, then to we've is, role the with to So, can that the be can one would clinical question, true question at specific, the answer progress that Marianne's a is your XX% is think should that's we're and The to bar in you patients in And I regimen cure. about have why, I X% the first see only remarks, a we question we in treatment when will that, really that interferon XXXX will plus need and And XXXX you end a for add the honing my later then prepared we on fact about an and can an of XXXX move the it an answer off-treatment if cure? peginterferon, weeks, either talked achieving end of or response. having XX of have that's therefore, have treatment is, beyond in response. functional replace role on role response of than hopefully next

the an infancy. your response So, to response answer on-treatment question in that still an off-treatment from is predicting is its

You XX% would for a answer? focused us get to will is, And rate. need least we're at that closer what on XXXX AASLD

Operator

from of the Our next Goldman Sachs. come will question with Paul Choi line

Kyuwon Choi

want sort over further wondering with maybe sketch and of But capital of the might the their Street maybe up to the XXXX relatively the follow you again and terms metrics how on years? Street you for out I expansion it's could that clinical you that progress X the are was couple products, into your on success maybe score -- seeing with I us areas?And the realize Sanofi these be immuno-oncology. next regarding and development can how RSV, Pfizer second, into and I you're Marianne, still question then commercial allocate given to in Gena's early expansion envision how stage. going thinking autoimmune again able of about of to to sketch regarding share how you're keep

Marianne De Backer

do want we'll Thank where to give program? the RSV a color start on Phil, bit stand you question. Maybe with we you, with the more Paul.

Phil Pang

Yes, definitely, Paul.

So, thank that you question. for

next straightforward the the bring And so we IND can forward is antibody, -- a which -- we lower So, and there's that population, tract PK straightforward, path the to others data. both respiratory tract believe attended do that infant MALRI both has blazed is demonstrate is respiratory months. we infection. by it to XX with lower RSV our human or relatively been infection XXXX after tract you're an answer covering of where, the believe I you what prevention in respiratory relatively obtain metapneumovirus, or infection, really and medically trying to And path is in Phase lower XX

GSK, Beyond that, are collaborator path our with partnered as the with robust determine most you program know, we to and fastest a and is working forward. this closely

can that's say about XXXX this I the So, what at time.

Marianne De Backer

And Paul, in I these stage Sung on are we first here to provide clarify at little new allocating discovery on the Phil. then ask we and to your capital you, Vir. that maybe Thank are areas are doing efforts bit background also want a question, at how first more

Sung Lee

thanks, Thanks, Yes. and Marianne, the question. for Paul,

So, directed there.Now, of that's discovery. majority add just in here will hepatitis capital oncology and The will require largely of Marianne directed allocation I the autoimmune our and delta. a still the mid-stage be efforts metrics, for to the terms in said, an investment want as at hepatitis be programs be B Paul, to in and allocation And Those something be would Vir. ongoing part not large the expensive will or doesn't here. our future, foreseeable capital

a GSK manufacturing. our III has to manufacturing obviously, related -- and capital allocation been we also past have liability towards the flu and Phase in the related to supply have Phase II the couple year-to-date, We of directed the items, activities, study sotrovimab heavily

write-down from the saw probably you take press we release, As manufacturing for did a those activities.

those behind to effectively costs, liability paid GSK flu now, and So, the us down. the costs has are

directed stage largely be going the the programs. clinical to So will again, forward capital

Marianne De Backer

innovation that if to we explore Yes. just external our help of there course, add, accelerate we programs programs, addition at are continue capital or are complement clinical And opportunities what I in allocation Vir. could us stage to to our predominantly here would doing

Operator

Joseph JPMorgan. the of from line Your Eric with question next comes

Unknown Analyst

It's for us. ] from [ couple ones Phil on A Eric.

last or of the up as maybe have do opportunity, then, virology something this question, following follow-up I business? you side [indiscernible]. just And external for historical the from new immuno-oncology more see the with First, so the the a side

Marianne De Backer

sorry, We Eric. understand well. could I'm you very very not

Unknown Analyst

hear can now? me Sorry, you

Marianne De Backer

Could you try again?

Unknown Analyst

Yes.

the So immuno-oncology would whether virology? following potentially, question you the the space historical looking complementary stated about just space in or opportunities question was you the were external -- of these in be on some the at from more and previous

Marianne De Backer

Okay. for Yes. that Eric. Thank question, you

we innovation forefront doing. mentioned, expertise looking we are and we can the as field. course, want perspective at of to, already have we platforms, from of believe So, that at in external really what in world-class do I we really stay our how are the accelerate our

we anything we that are could [indiscernible]. stay looking help as at there so, us And

beyond. can both be infectious that in diseases or So,

Unknown Analyst

And Okay. program. one the HBV about just quick one

NUC that in on XQ by Looking guided NUCs? to follow-up you've would off point still patients to off-treatment expect forward be the now 'XX, the to you that or

Phil Pang

Pang. is for This Phil the you question. Thank

So, them be they the post protein, that a XX demonstrated antigen you know, sopped transcriptase and suppress that is they NUCs. happens for period off it's to further. is I time And -- you reverse loss, unexpected another DNA surface which don't treatment, what the follow a X sure antigen have bag, then -- that they're would to you make expect on impacted nucleoside be somewhat but NUCs weeks that, as will relapse be only therefore, surface for and is, can of treatment, still say of though NUC to HBV by at usually inhibitor. they once will actually least usually will they months they've lost continue will they mixed

a reverse forward the our course, to it's of although, think drugs is still we're what data on match, guiding a that I looking inhibitor. nucleoside transcriptase but we're off what perfect not to So, and post-treatment

Operator

H.C. with line question Patrick comes Trucchio Wainwright. next the Your of from

Patrick Trucchio

III First, regulatory track. see confidence if bar be or delta you would that in for can And Specifically, HDV? to SOLSTICE that's program? a the need what next the all generated directly steps and give HDV you of a hepatitis what for across HBV on and is program to after to on you able I'm readout, Phase this program delta SOLSTICE into would been wondering secondly, in approval possibly based move be the data the discuss

Marianne De Backer

Yes. for you Thank question. that

do on So, set as suppression, what the any as delta you is as That's inflammation. to want therapy add liver to we regulatory is reduction more also to of chronic bar the color in the of in see how SOLSTICE? side.Phil, well want you know, viral goal

Phil Pang

Yes, definitely, Marianne.

HDV in that, of one a to is the That were RNA is for is another at. to look on normalization and set the allow regulatory development. to HBV said, marker an undetectability too benefit. want exactly, That bars decline So with that of drug at as bar ALT. long tightly was the think Marianne I incentivized early I we bars think clinical associated another that's of look And the that bar of RNA. But one is

those So, space. we'll relatively small And to patients period going bars. you core a do want I having think remind wait time. a that can at the that if for to to of see this in pathway like are treated be given in need next short have unmet of regulatory data we're accelerated mentioned But we're remarks, prepared both I know just my I've be. that to what be steps AASLD, to be for looking of able the to to what the looks going as warranted,

Operator

comes question next Roanna the Partners. with Your Ruiz of line from Leerink

Nik Gasic

of developing guess, aspect is the us antibody the A from in your aside This of XXXX I the what well? targeting you you the differentiated might this secondly, flu from some B apply is talk B? from flu a the status A flu XXXX how A in to about development discuss flu first, little Nik as And XXXX, you antibody you then experience and of is learnings Roanna. bit against which Maybe next-generation could XXXX Gasic could could and B? remind for on

Marianne De Backer

Yes. Yes. Thank question, you for that Nik.

provide start will then a Phil I So and more bit depth. ask to

XXXX differences the B. a major that of rightly is proven mechanism inhibitor, of work fact different as It's antibody, has first before. It's a and all, covers action. also and XXXX, that flue A So of neuraminidase to a both you flu action it our of mechanism is been out, flu and the one that pointed between next-generation

We the have also that seen XXXX. in vitro more potent is antibody than

make someone based in on elapses and a initial there's So, how some much between being clinical it we that primary being next-generation relevant in we are for we learnings that already very our XXXX, out have does ].And there's Obviously, of dosed is to that remarks, include interesting someone trials, also fever from you really here infected. time a seen difference, whether pointed have and for his analysis. it as differentiating relates Phil your endpoint. data learnings feel lot prepared important the our components antibody It [ as

little maybe, about Phil, continuing the more talk beginning next we can planning of So a you steps.And [ these and of all to analysis by to we data us, we're are, and next that bit more the year. about is course, ] that can are, learn ongoing for course, our as learnings analyze data of very learnings cross as important and for much

Phil Pang

Marianne. Definitely,

your clinic. vitro the So true results into vivo exists, Nik, is that one questions especially the and regardless it's in infectious the space disease, does for how in always translate or of critical of

pointed between findings And so, efficacy. vivo addition is do out, Marianne dose critical questions, clinical the all one how we of in to and lessons in that the calibrate

as a the So, as the company mentioned of necessary the is data and concentration that previously, understand first vivo to will run of the been in people. as advantages PD, to mentioned to having and we PK and prophylactic and really really that now will flu -- ever translate calibrates have soon to trial, have I one my may in which findings really us in allows dose vitro outpatient

that that, will possible. very and to we're clinical development, that sure small mentioned a gap what Marianne to part endpoints to as trying XXXX about of studies and XXXX, is make addition series gap as help and is in to useful planning bridge so, really XXXX be timing, calibrate already our using -- that of that And a inform

Nik Gasic

Helpful.

I as we [ [indiscernible] thinking guess, how instead should WHO you are using ] flu, and -- this trial WHO your both CDC primary, future think and/or So, future trials in about which feature CDC about endpoints that fever? design, the

Phil Pang

Yes.

even advanced be little may a we think bit I beyond more So, that.

is they recognizing certainly do XX.X temperature, Celsius. important that you WHO, degree -- XX.X if basically would the are now the between or versus -- slightly We fever and CDC temperature different an a have

any So, that, in by we other post-hoc well covered are well looking that into as XXXX analysis. symptoms as are

to that to we will But fever consider put all decide. going together certainly, we're forward. So, be what a moving of part

Operator

Your Cowen. the of line Privitera will TD Eva from next question come with

Eva Privitera

point? on measures the do Approximately to each expect And We have trial you what of SOLSTICE many worth data report end expect? how with should And in AASLD. are efficacy addition to pretty treatment groups we at data one balanced? the patients primary

Marianne De Backer

Thank Eva. show trial. be this the time I really our we obviously, that say very will will initial you, that, very just first data from SOLSTICE also

with But data and mentioned Phil? in will remarks, see on, Phil arms. this alone some still combination.Anything of XXXX the XXXX the alone, as of participants initial there, to course, his So, of a number is then we in each small prepared add

Phil Pang

or pointed at, arms. work And No, or not it monotherapy just And would small I X to couple to those a of together. in very don't then, they a looking they the enrolled designed and is, understand antiviral we or would don't the maybe together be Marianne activity drugs -- in monotherapy which if we combination study -- things essentially, think I'll antiviral showed roll how going the therapy. really combination signs to patients able didn't out, into be work clarify that the as a way number show the are is arm of activity, of treatment

to of look sharing design the trial, AASLD. data we be the to and forward at going that's So,

Eva Privitera

the getting is How that to bar HDV decline? important granted X levels, undetectable log the regulatory is

Phil Pang

So, to question higher getting is, than your I the to is certainly X think a that a bar undetectable answer log decline.

I XX%. with before, I good undetectability correlates clinical think about And is current that there that data suggesting with the well think clinical I therapy, that, mentioned outcomes. as it's

the time. XX%, been of weeks I we or following full than that And of course, that question the of fact after much say can our period shorter So, therapy. is, better do a for given XX happens we patients that, a that, have would meet

AASLD say, and to think let see speak. I So, we'll the and wait just has science what have to

Operator

from Company. of comes question with Needham & the Stringer Joseph next Your line

Joseph Stringer

one quick would of Phase you in to of do a what type half need Just announce I that year? And next in -- the plan would or proceed confidence next in program. to data steps what to program? you to The that give what HIV see on second readout, the you

Marianne De Backer

do you Thank want to question, that? Joey. Phil, take Yes. that you for

Phil Pang

Definitely.

it So, as healthy you study in is study. Phase volunteers. Joey, immunogenicity I noted, It an is a

immunogenicity. is, endpoint primary the obviously, plus safety So,

is example, And so, of that sorry, the HLA overcome. HIV or can restriction T They're an cells, response, something they And restricted don't that unique harder we not, a are next that cassette. need is, T question we responses if mount the we cells the the insert, we what MHC-E, calling which be what T fight. cells to they multiply they special responses immune mucosa. have by have be then very be cell They memory really type is which of -- be to and T if very do is, we cell virus are are they to understanding will in which to for have for to creating possible, of, reside and need before the might whether creating? CDX third, obviously ready would CDX is answer do, Then T expect understand an impact. to don't which we're CDX rather insert, against the immunogenic, Are what type effector -- one,

in we are So, looking immunologic are things for our all those readouts.

data We from initial immunologic readouts those are next planning year.

Marianne De Backer

the for next for HCMV-based then, call, add data the what vaccine cell initial will seen maybe investigational HBV. be is guiding T Right. also HIV that, I've T focused our to helpful just learning we really platform, those And us cells or, that on in

Operator

Marianne over I'll turn to now remarks. conference closing back Backer for the Dr. De

Marianne De Backer

Okay. Thank these leave you takeaways. for want couple and thank of all close, you, with just operator, to your and again To I attention time today. you

delta programs, chronic Phase and presented to clinical November continue can ongoing expect hepatitis and trials clinical progress B be you from chronic XX. our II we hepatitis data new on on to make First, our

are we expanding beyond focus and immuno-oncology. diseases first our Second, disease, strategic autoimmune to infectious

BARDA. antibodies, the from and of discovery the thanks billion time that core monoclonal and antibody and thank hepatitis your all lastly, new clinical to in to $X.X end today. us again, existing platform. Yet have our it your available external help we delta and that may advancement funding you pioneering joining B additionally, you, the appreciate We evaluate also in really our And interest trials RNA-delivered strengthen opportunities call. supports and our investments of and Vir. are of We the complementary for you Operator, us enables the pipeline.So cash platforms

Operator

does for This Thank you joining. today's all meeting. conclude

disconnect. now may You

Vir Biotechnology (VIR) 2 Nov 232023 Q3 Earnings call transcript